The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.

ABSTRACT: Several therapeutic agents have been approved for treating multiple myeloma, a cancer of bone marrow-resident plasma cells. Predictive biomarkers for drug response could help guide clinical strategies to optimize outcomes. In this study, we present an integrated functional genomic analysis of tumor samples from patients multiple myeloma that were assessed for their ex vivo drug sensitivity to 37 drugs, clinical variables, cytogenetics, mutational profiles, and transcriptomes. This analysis revealed a multiple myeloma transcriptomic topology that generates "footprints" in association with ex vivo drug sensitivity that have both predictive and mechanistic applications. Validation of the transcriptomic footprints for the anti-CD38 mAb daratumumab (DARA) and the nuclear export inhibitor seline

SUBMITTER: Sudalagunta PR 

PROVIDER: S-EPMC11733535 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature